1.Utilization and characteristics of social capital in public hospital development
Xiaohua YING ; Liang ZHANG ; Leilei YAN ; Linping XIONG ; Shengkang LU ; Ping LI ; Pei LIU
Chinese Journal of Hospital Administration 2011;27(9):646-649
The paper described the necessity of social capital utilization for public hospitals, and analyzed the model and characteristics of public hospital financing. It is pointed out that the key to the public-benefit nature in the financing calls for distinguishing responsibilities of the government and the market, defining the reasonable level and manner for investors' return, and building corresponding incentive mechanism and supervision mechanism.
2.Tension-force induced cyclooxygenase-2 expression mediated by microfilament in human periodontal ligament fibroblast.
Pei-ying XIONG ; Sheng-gao HUANG ; Jian-xing ZHANG
West China Journal of Stomatology 2006;24(4):353-356
OBJECTIVETo study the role of microfilament polymerization in menchanotransduction by human periodontal ligament fibroblast (hPDLFs).
METHODSIn tension-force group, hPDLFs were treated by tension-force values of 18% for 8 h, 16 h, 24 h. In tension-force and inhibitor group, the sample was treated with 5 microg/mL cytochalasin B before using tension-forece. Each sample was collected and the expression of cyclooxygenase-2 was measured by using immunohistoche staining.
RESULTSIn tension-force group, the expression of cyclooxygenase-2 enhanced with the extension of loading time. In tension-force and inhibitor group, cyclooxygenase-2 expression was depressed and had no relation with loading time.
CONCLUSIONTension-force induced cyclooxygenase-2 expression is mediated by microfilament, disruption of the microfilament polymerization will destroy mechanotransduction in hPDLFs.
Actin Cytoskeleton ; Cells, Cultured ; Cyclooxygenase 2 ; Fibroblasts ; Humans ; Mechanotransduction, Cellular ; Periodontal Ligament ; Stress, Mechanical
3.Method performance verification of the clinical chemiluminescence immunoassay
Xiu-Ming ZHANG ; Jun-Hua ZHUANG ; Song-Bai ZHENG ; Jian-Hua XU ; Ji MA ; Lei SUN ; Lian-Ying LIN ; Pei-Feng KE ; Wei-Xiong LIANG
Chinese Journal of Laboratory Medicine 2003;0(11):-
Objective To establish a method performance verification project and experimental method for the clinical chemiluminescence immunoassay.Methods Referring to CLSI evaluation protocols and pertinent literature,and by combining our actual works,we designed a verification procedure and experimental method.By Using these above,the precision,accuracy,analytical sensitivity,analytical measurement range,clinical reportable range and biotic interval of AFP on the Bayer Centaur 240 chemiluminescence immunoassay system were verificated.Results would be compared with the declaration of the manufacturer or desirable specifications derived from biologic variation.Results The results showed that the between-day inaccuracy on AFP levels at 77.4 ng/ml and 168.0 ng/ml was 5.70% and 4.84% respectively,these were consistent with manufacturer's inaccuracy claimed.The relative bias between the results measured for calibrator at four levels and target value was less 5.0%,and the relative bias between the results measured for EQA control sample at five levels and target value was-3.4% to 11.9%.Lower limit of detection was 1.04 ng/ml,lower slightly manufacturer's analytical sensitivity claimed.Biologic limit of detection was 2.65 ng/ml-3.53 ng/ml,functional sensitivity was 3.53 ng/ml.Analytical measurement range was 3.53-912.00 ng/ml,within manufacturer's liner range claimed.Clinical reportable range was 3.53-182 400.00 ng/ml.Reference interval was 0.6-7.7 ng/ml,within manufacturer' s claimed.Conclusions The main performances of the detection system are accorded with the declaration of the manufacturer.The performance verification procedure and experimental method of our research ars simple and practical,which has important significations for building medical laboratory and laboratory accreditation, improving quality of the chemiluminescence immunoassay.
4.Cause analysis and nursing of organ damage after in vitro fertilization and embryo transfer
Yongli LYU ; Yinglu WAN ; Pei HE ; Ying XIONG
Chinese Journal of Practical Nursing 2017;33(33):2597-2600
Objective Through retrospective analysis of the causes of organ damage after in vitro fertilization embryo transfer,we put forward targeted prevention and take corresponding nursing measures to promote the prognosis of patients. Methods Selected 14 patients who suffered from organ damage after paracentes is in vitro fertilization and embryo transfer in our hospital.The causes were analyzed,and the treatment and nursing protocols were determined according to the kind and severity of the injured organs. Results 14 cases of organ injury patients with treatment and nursing gauze to stop bleeding, antibiotics, conservative treatment, hemostatic anti shock, indwelling catheter bladder irrigation, ureteral catheter and surgery were given symptomatic, were cured, hospitalization time was 3- 10 days. Conclusions The reasons for such patients, clinical observation and analysis of nursing treatment, let clinical nurses accumulate nursing experience in such patients, can timely take corresponding nursing measures,In order to improve the related nursing level of assisted reproductive technology.
5.The overview of the property system and characterization techniques of Chinese medicine materials before the pharmaceutical
Zhi-wei XIONG ; Ru-xi NING ; Ying-xia ZHAO ; Xiao-xin HU ; Bing YANG ; Yuan-pei LIAN ; Liang FENG ; Xiao-bin JIA
Acta Pharmaceutica Sinica 2021;56(8):2048-2058
At present, the modernization of Chinese medicine preparations (CMPs) is still a challenging task. The 3 typical Chinese medicine materials (CMMs) used for preparing CMPs are the powders, extracts, and components of Chinese medicine and their properties of CMMs are important for designing CMPs. Basing on our long term research, we have established a property system for CMMs according to the state of CMMs under an exactly condition and according to the interaction characteristics between substances. The property system could be divided into 5 categories: material composition, spatial structure, body property, surface property, physicochemical properties, and they could also be divided into 18 subcategories. Furthermore, we also established the corresponding index and characterization system, where the 61 indexes and characterization techniques were systematically summarized. At last, we hope that the article will promote the modernization of CMPs.
6.Effect of continuously compressive pressure on the expression of RANKL mRNA in human periodontal ligament cells in vitro.
Sheng-gao HUANG ; Jian-xing ZHANG ; Pei-ying XIONG ; Ming-lang WANG
Journal of Central South University(Medical Sciences) 2006;31(4):518-522
OBJECTIVE:
To determine the effect of continuously compressive pressure (CCP) on the expression of receptor activator of nuclear factor kappa B ligand (RANKL) in human periodontal ligament cells (HPDLCs) and to investigate the role of RANKL in alveolar bone rebuilding during orthodontic tooth movement.
METHODS:
The primary HPDLCs were isolated from human periodontal ligament by explanting enzymatic digestion with trypsin and collagenase to establish a pressure model. Top-bottom axial pressures (1, 2, and 3 g/cm(2)) were laid on HPDLCs for 0.5, 1.5, 6, 12, 24, and 48 h, respectively. The RANKL expression was identified by the reverse transcription-polymerase chain reaction (RT-PCR) at the mRNA level.
RESULTS:
The expression of RANKL mRNA significantly increased in a time-dependent manner (P<0.01), so did the value of pressure, especially in the 2 g/cm(2) group (P<0.05).
CONCLUSION
CCP can up-regulate the expression of RANKL mRNA in human periodontal ligament cells.
Compressive Strength
;
Humans
;
Periodontal Ligament
;
cytology
;
metabolism
;
RANK Ligand
;
biosynthesis
;
genetics
;
RNA, Messenger
;
biosynthesis
;
genetics
;
Receptor Activator of Nuclear Factor-kappa B
;
genetics
;
metabolism
;
Stress, Mechanical
7.Clinical trial of the valsartan/amlodipine compound preparations and the single of two drugs for treatment of moderate and severe hypertension
Ji-Feng ZHANG ; Yi-Peng MO ; Yong-Jun YING ; Lin XU ; Pei-Yi XIE ; Xiong LI
The Chinese Journal of Clinical Pharmacology 2014;(12):1081-1082,1095
Objective To evaluate the clinical efficacy and safety of valsartan/amlodipine compound preparations versus amlodipine combined with valsartan for treatment of moderate and severe hypertension.Methods One hundred and twenty subjects with hypertension ( BP≥160/100 mmHg ) were recruited from our hospital in the outpatient ser-vice department.The recruited 120 cases were randomized divided into treatment group and control group with each group of 60 cases.Patients in the treatment group were given valsartan /amlodipine compound prepa-rations (80/5) 85 mg one pil per day for 8 weeks and patients in the control group were given amlodipine 5 mg qd po plus valsartan 80 mg qd po with a treatment period of 8 weeks.The blood pressure and adverse drugs reaction ( ADR) between the two groups were recorded and com-pared.Results The blood pressure was significant decreased in both of two groups after taken the medicine but no statistical difference between the two groups was found ( P>0.05 ).And ADR in the two groups was also no statistical difference ( P >0.05 ).Conclusion The monolithic compound antihypertensive valsartan/amlodipine was reliable and similar to that of monolithic joint valsartan amlodipine.
8.Differential gene expression of liver carcinoma cell after transfection of by ARL-1 with microarray.
Da-nian TANG ; Yong-guo LI ; Jun-min WEI ; Xiang-dong YANG ; Min-wei ZHU ; Pei WU ; Xiong-ying MIAO
Chinese Journal of Surgery 2003;41(3):180-182
OBJECTIVETo study the difference of the gene expression profile and to identify the different expression after transfection of the ARL-1 gene.
METHODSThe cDNA probes were synthesized from total RNA of study group and control group, which was differentially hybridized to cDNA chips and confirmed by a gene specific semiquantitative reverse transcription polymerase chain reaction (RT-PCR).
RESULTSSix kinds of gene expression were increased and 9 kinds of gene expression were decreased. The findings were correlated with protein metabolism, signal pathway, metastasis, and drug resistance.
CONCLUSIONScDNA chips showed that gene expression profile of liver carcinoma cell was changed after transfection of the ARL-1 gene. It is a useful method in understanding the mechanism of drug resistance.
Aldehyde Reductase ; genetics ; Drug Resistance, Neoplasm ; Gene Expression Profiling ; Humans ; Liver Neoplasms ; drug therapy ; genetics ; Oligonucleotide Array Sequence Analysis ; Transfection
9.CXCL1 as a potential therapeutic target for diabetic nephropathy
Xin HU ; Lizhuo WANG ; Yao ZHANG ; Wenjun PEI ; Jinhan CHENG ; Chaoqun XIONG ; Yue QIAN ; Qiuheng ZHANG ; Xu WU ; Ying YANG ; Jialin GAO
Chinese Journal of Endocrinology and Metabolism 2023;39(12):1056-1066
Objective:To screen highly expressed inflammatory factors in diabetic nephropathy models using protein microarray, analyze differential genes and their regulatory networks, and predict potential therapeutic small molecular compounds.Methods:The inflammatory factor microarray was used to screen the inflammatory factors with the same tendency in the cell model and animal model of diabetic nephropathy. The differential genes screened by R language were enriched and analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG). STRING builds a protein interaction network online, Cytoscape software analyzes the core subnetwork, and Connectivity Map searches for and predicts small molecule compounds.Results:Diabetic nephropathy model was established using 16-week-old db/db mice and mesangial cells stimulated with high glucose, and the expression of C-X-C motif chemokine ligand 1(CXCL1) was elevated in both models. Multiple GEO datasets indicated a strong association between the high expression of CXCL1 and diabetic nephropathy. Specifically, GSE30122 showed an upregulation of 30 genes and a downregulation of 23 genes. GO enrichment analysis focused on biological processes such as humoral immunity and lipopolysaccharide response; While KEGG enrichment was mainly in pertussis and coagulation cascade pathways. CytoHubba identified 10 hub genes, such as ALB, LUM, and CXCL1. In addition, 10 small molecule compounds were predicted as potential therapeutic drugs using Connectivity Map.Conclusions:CXCL1 may serve as a key gene in the occurrence and development of diabetic nephropathy. ALB, LUM, CXCL1, MMP7, TGFBI, CCL2, S100A4, SOX9, VCAN, and CLU may participate in the regulatory network centered around CXCL1. There are 10 small molecular compounds demenestrating the potential to be therapeutic agents.
10.Therapeutic effect of sirolimus against chronic allograft nephropathy in kidney transplant recipients.
Chang-xi WANG ; Si-yang CHEN ; Li-zhong CHEN ; Long-shan LIU ; Ji-guang FEI ; Su-xiong DENG ; Jiang QIU ; Jun LI ; Ke-li ZHENG ; Pei-gen WU ; Yu-lian JI ; Lan-ying ZHU
Journal of Southern Medical University 2007;27(12):1924-1926
OBJECTIVETo investigate the efficacy and safety of sirolimus in management of chronic allograft nephropathy (CAN).
METHODSA retrospective study was conducted involving 31 CAN patients followed up since March 2002, who experienced a change from a calcineurin inhibitor (CNI)-based regimen to a SRL-based regimen. Serum creatinine (Cr) in these patients was compared before and after the regimen change, and the adverse events associated with SRL were analyzed.
RESULTSTill March 2007 when the study closed, 15 patients reached the primary endpoint for resuming dialysis, 8 had improved and 8 had stable renal function. In patients with high Cr(0)(> or =3 mg/L, n=12), 9 resumed dialysis and 2 had improved renal function, but one of the patients with renal improvement eventually died due to infection; in the patients with low Cr(0)(<3 mg/L, n=19), 5 resumed dialysis, 8 had stable renal function and 6 had improved renal function, showing significant difference between the 2 groups (P=0.003). Altogether 14 patients reached the secondary endpoint for ceasing SRL for severe infection (5 patients, of whom 4 resumed dialysis and 1 died of infection) or adverse events associated with SRL (9 patients, of whom 4 resumed dialysis, 2 had stable and 3 had improved renal function). Hyperlipidemia (51.6%), leukocytopenia (41.9%), mouth ulcer (29.0%) and liver function lesion (16.1%) were the commonest adverse events in these patients, and totalling 13 severe adverse events were recorded, including 2 fatal cerebral hemorrhage, 3 fatal infection episodes, and 8 pulmonary and urinary infections that require hospitalization.
CONCLUSIONConversion from a CNI-based to SRL-based regimen can be effective for some CAN cases, especially for those with Cr(0) below 3 mg/L. Attention must be given to adverse events like hyperlipidemia and leukocytopenia, as well as the related cerebral vascular accidents and infections.
Adult ; Aged ; Chronic Disease ; Creatinine ; blood ; Female ; Humans ; Immunosuppressive Agents ; adverse effects ; therapeutic use ; Kidney Function Tests ; Kidney Transplantation ; pathology ; Male ; Middle Aged ; Retrospective Studies ; Sirolimus ; adverse effects ; therapeutic use ; Transplantation, Homologous ; Treatment Outcome ; Young Adult